Adequate protein supports energy levels and prevents the muscle loss that can accompany aggressive caloric restriction on GLP-1 therapy
Retatrutide is a novel 'triple agonist' developed by Eli Lilly, targeting the GLP-1, GIP, and glucagon receptors simultaneously
Generic Akkermansia supplements Several companies now sell Akkermansia muciniphila as a standalone supplement at lower price points than Pendulum
Long-term safety and efficacy of glucagon-like peptide-1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study
The overall physiological effects include promoting insulin secretion, inhibiting glucagon release, delaying gastric emptying, and influencing appetite
Beyond type 2 diabetes, GLP-1 drugs might also benefit patients with type 1 diabetes